2. Search Result
Search Result
Results for "

N-Cadherin

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

7

Peptides

1

Natural
Products

5

Recombinant Proteins

6

Antibodies

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13541
    ADH-1
    5+ Cited Publications

    		 Cadherin Cancer
    ADH-1, an N-cadherin antagonist, inhibits N-cadherin mediated cell adhesion.
    ADH-1
  • HY-13541A
    ADH-1 trifluoroacetate
    5+ Cited Publications

    		 Cadherin Cancer
    ADH-1 trifluoroacetate is an N-cadherin antagonist, which inhibits N-cadherin mediated cell adhesion.
    ADH-1 trifluoroacetate
  • HY-P11288A
    ANT308 TFA

    		PACAP Receptor Apoptosis Cancer
    ANT308 TFA is a vasoactive intestinal polypeptide (VIP receptor) antagonist. ANT308 TFA significantly enhances the activation and proliferation of T cells. ANT308 TFA inhibits the migration and metastasis, induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin. ANT308 TFA can be used for the study of acute myeloid leukemia (AML) and uveal melanoma (UVM) .
    ANT308 TFA
  • HY-P11346
    N-Cadherin mimic peptide

    		Cadherin Inflammation/Immunology
    N-Cadherin mimic peptide is a N-cadherin agonist. N-Cadherin mimic peptide promotes N-cadherin homodimerization via enhancing β-catenin signaling, inducing early chondrogenesis and cartilage matrix production in mesenchymal stem cells (MSCs). N-Cadherin mimic peptide is promising for research of MSC-based cartilage regeneration .
    N-Cadherin mimic peptide
  • HY-P11288
    ANT308

    		PACAP Receptor Apoptosis Cancer
    ANT308 is a vasoactive intestinal polypeptide (VIP receptor) antagonist. ANT308 significantly enhances the activation and proliferation of T cells. ANT308 inhibits the migration and metastasis, induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin. ANT308 can be used for the studies of acute myeloid leukemia (AML) and uveal melanoma (UVM) .
    ANT308
  • HY-173557
    PRMT7-IN-2

    		Histone Methyltransferase Apoptosis Cancer
    PRMT7-IN-2 (A33) is a selective PRMT7 inhibitor with an IC50 of 0.50 μM. PRMT7-IN-2 arrests cell cycle at G0/G1 phase, induces cell apoptosis, and inhibits cell growth in vivo and in vitro. PRMT7-IN-2 decreases the monomethylarginine level of PRMT7, increases expression of epithelial marker (E-cadherin, and reduces expression of mesenchymal markers such as N-cadherin, Vimentin, and ZEB2 .
    PRMT7-IN-2
  • HY-N15267
    Ovalitenone

    		FAK Akt mTOR Cancer
    Ovalitenone is a flavonoid compound that can be isolated from the plant Millettia peguensis. It shows no cytotoxic effects on lung cancer H460 and A549 cells, but it significantly inhibits anchorage-independent growth, CSC-like phenotypes, colony formation, and the migration and invasion capabilities of cancer cells. Ovalitenone can significantly reduce the levels of N-cadherin, snail, and slug, while increasing E-cadherin, thus inhibiting the EMT pathway. Additionally, Ovalitenone suppresses the signaling pathways regulated by focal adhesion kinase (FAK), ATP-dependent tyrosine kinase (AKT), mammalian target of rapamycin (mTOR), and cell division cycle 42 (Cdc42) .
    Ovalitenone
  • HY-173560
    SHP2 ATTEC degrader-1

    		ATTECs SHP2 Apoptosis Cancer
    SHP2 ATTEC degrader-1 is a SHP2 ATTEC degrader. SHP2 ATTEC degrader-1 has degradation rate of 83.31 at 1.0 μM for 24 h in the PANC-1 cell line. SHP2 ATTEC degrader-1 inhibits cell growth in vivo and in vitro. SHP2 ATTEC degrader-1 induces apoptosis and increases the expression of the epithelial marker ( E-cadherin)， and reduces the expression of interstitial markers (such as N-cadherin, Vimentin) (Pink: LC3 ligand (HY-174085); Black :linker HY-140468; Blue: SHP2 ligand (HY-174084) .
    SHP2 ATTEC degrader-1
  • HY-172551
    anti-TNBC agent-9

    		Apoptosis Cadherin MMP Bcl-2 Family Cancer
    anti-TNBC agent-9 (Compound 3as) is an anti-cancer agent for triple-negative breast cancer (TNBC). anti-TNBC agent-9 exhibits significant inhibitory activity against MDA-MB-453 cells with an IC50 value of 8.5 μM. anti-TNBC agent-9 inhibits tumor cell migration by upregulating E-cadherin and downregulating N-cadherin, matrix metalloproteinase 2 (MMP2), and MMP9. anti-TNBC agent-9 induces apoptosis by increasing the expression of the pro-apoptotic protein BAX and decreasing the expression of the anti-apoptotic protein BCL-2, thereby inhibiting tumor cell proliferation .
    anti-TNBC agent-9
  • HY-RS24094
    Cdh2 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Cdh2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cdh2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cdh2 Rat Pre-designed siRNA Set A
    Cdh2 Rat Pre-designed siRNA Set A
  • HY-115669
    Pentachloropseudilin
    1 Publications Verification

    Antibiotic A 15104 Y; PClP

    		 Myosin TGF-β Receptor Cancer
    Pentachloropseudilin (Antibiotic A 15104 Y; PClP) is a reversible and allosteric potent inhibitor of Myo1s (class 1 myosins) with IC50s range from 1 to 5 μM for mammalian class-1 myosins and greater than 90 μM for class-2 and class-5 myosins. Pentachloropseudilin is a potent inhibitor of transforming growth factor-β (TGF-β)-stimulated signaling, with an IC50 of 0.1 to 0.2 μM for TGF-β .
    Pentachloropseudilin
  • HY-19987R
    BML-284 (Standard)

    		Wnt Cancer
    BML-284 (Standard) is the analytical standard of BML-284. This product is intended for research and analytical applications. BML-284 is a potent and cell-permeable Wnt signaling activator. BML-284 induces TCF-dependent transcriptional activity with an EC50 of 700 nM .
    BML-284 (Standard)
  • HY-19987
    BML-284
    Maximum Cited Publications
    33 Publications Verification

    		 Wnt Cancer
    BML-284 is a potent and cell-permeable Wnt signaling activator. BML-284 induces TCF-dependent transcriptional activity with an EC50 of 700 nM .
    BML-284
  • HY-19987A
    BML-284 hydrochloride

    		Wnt Cancer
    BML-284 hydrochloride is a potent and cell-permeable Wnt signaling activator. BML-284 induces TCF-dependent transcriptional activity with an EC50 of 700 nM .
    BML-284 hydrochloride
  • HY-123931
    ZLDI-8
    1 Publications Verification

    		 Notch Phosphatase Apoptosis Cancer
    ZLDI-8 is a Notch activating/cleaving enzyme ADAM-17 inhibitor and inhibits the cleavage of Notch protein. ZLDI-8 decreases the expression of pro-survival/anti-apoptosis and epithelial-mesenchymal transition (EMT) related proteins. ZLDI-8 is also a competitive and irreversible tyrosine phosphatase (Lyp) inhibitor with an IC50 of 31.6 μM and a Ki of 26.22 μM. ZLDI-8 inhibits the growth of MHCC97-H cells with an IC50 of 5.32 μM .
    ZLDI-8

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: